Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care.

World Allergy Organ J · 2020 · PMC7753940 · PMID 33376573

Europe PMC DOI

hedged sentence

0.3532

closest p · 7.1× alpha

0.3532

boldest claim

The sentences

did not reach statistical significancep = 0.3532not close (p > 0.1)

Patients with AR and asthma had better asthma control assessed by RDAC (effect size = 4.4%; p = 0.0045), OAC (effect size = 4.1%; p = 0.0037) and by GINA control status in the year after MP-AzeFlu prescription compared with the year prior to prescription, although the latter association did not reach statistical significance (effect size = 1.6%; p = 0.3532) ( Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.